Biologics Contract Development

Global Biologics Contract Development Market to Reach US$12.6 Billion by 2030

The global market for Biologics Contract Development estimated at US$8.2 Billion in the year 2024, is expected to reach US$12.6 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Mammalian Source, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$6.0 Billion by the end of the analysis period. Growth in the Microbial Source segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 7.3% CAGR

The Biologics Contract Development market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.9% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.

Global Biologics Contract Development Market - Key Trends & Drivers Summarized

Why Is Biologics Contract Development Gaining Momentum in the Biopharmaceutical Industry?

Biologics contract development has become an essential part of the pharmaceutical ecosystem, enabling biotech firms and large pharmaceutical companies to accelerate drug discovery, streamline product development, and optimize manufacturing processes. With the increasing complexity of biologic drugs such as monoclonal antibodies, gene therapies, and recombinant proteins, companies are increasingly outsourcing key stages of biologics development to specialized contract development organizations (CDOs) that offer expertise, regulatory compliance, and advanced manufacturing capabilities. The demand for biologics is surging due to their effectiveness in treating chronic diseases such as cancer, autoimmune disorders, and rare genetic conditions. However, the high costs and technical complexities associated with biologic drug development pose significant challenges for in-house research and development teams. As a result, pharmaceutical companies are leveraging the expertise of CDOs to conduct early-stage research, cell line development, process optimization, and analytical testing, thereby reducing costs and accelerating time-to-market. With the rise of biosimilars and personalized medicine, the need for efficient contract development services is expected to grow substantially in the coming years.

How Are Technological Advancements Enhancing Biologics Contract Development?

The integration of cutting-edge technologies such as artificial intelligence (AI), automation, and single-use bioprocessing systems is transforming biologics contract development, improving efficiency, scalability, and quality assurance. AI-driven drug discovery platforms are enabling faster identification of therapeutic candidates by analyzing vast datasets and predicting molecular interactions with high accuracy. This accelerates the initial stages of biologic development and reduces the time required for preclinical research. Additionally, the adoption of single-use bioreactors and modular production facilities is enhancing the flexibility and cost-effectiveness of biologic manufacturing. These innovations allow contract development organizations to quickly adapt to changing client requirements and improve production efficiency for small-batch and personalized biologic drugs. Moreover, advancements in cell line engineering and gene editing techniques such as CRISPR are improving the productivity and stability of biologic drug candidates, ensuring higher yields and improved therapeutic efficacy. As biologic therapies become more specialized and complex, technological innovation will continue to drive the evolution of contract development services.

What Market Trends Are Driving the Growth of Biologics Contract Development?

One of the most significant trends shaping the biologics contract development market is the increasing demand for biosimilars and novel biologic therapies. As patents for blockbuster biologics expire, pharmaceutical companies are focusing on developing biosimilars to capture market share and provide more affordable treatment options. Contract development organizations play a crucial role in facilitating biosimilar development by providing expertise in analytical characterization, bioequivalence testing, and regulatory compliance. Another key trend is the shift toward personalized medicine and cell and gene therapy development. With advancements in genomic research and precision medicine, pharmaceutical companies are investing in biologic therapies tailored to individual patients. This shift is driving the demand for contract development services that specialize in advanced cell therapies, viral vector production, and customized biologic formulations. Additionally, regulatory agencies are introducing streamlined approval pathways for innovative biologics, encouraging companies to accelerate their development timelines through strategic outsourcing partnerships with contract development organizations.

What Are the Key Growth Drivers for the Biologics Contract Development Market?

The growth in the Biologics Contract Development market is driven by several factors, including increasing demand for biologic drugs, rising investment in biosimilars, and the growing complexity of biologic manufacturing. As pharmaceutical companies seek to optimize costs and accelerate drug development timelines, contract development organizations are playing an increasingly critical role in the industry. The expansion of biologics manufacturing infrastructure, particularly in emerging markets, is further propelling market growth by providing cost-effective development solutions to biotech firms and small pharmaceutical companies. Additionally, the increasing adoption of automation, AI, and advanced bioprocessing technologies is enhancing the efficiency and scalability of biologics contract development services. As regulatory agencies continue to support the expansion of biologics and biosimilars, contract development organizations are expected to see sustained growth, reinforcing their position as key partners in the future of biopharmaceutical innovation.

SCOPE OF STUDY:

The report analyzes the Biologics Contract Development market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Source (Mammalian Source, Microbial Source, Other Sources); Service (Process Development Service, Cell Line Development Service, Other Services); Indication (Oncology Indication, Immunological Disorders Indication, Cardiovascular Disorders Indication, Hematological Disorders Indication, Other Indications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

• Biovian Oy
• Boehringer Ingelheim International GmbH
• Catalent, Inc.
• Celonic AG
• Charles River Laboratories
• FUJIFILM Corporation
• Kemwell Biopharma Pvt. Ltd.
• Lonza Group
• LOTTE BIOLOGICS
• Mabxience Holding S.L.
• Polymun Scientific Immunbiologische Forschung GmbH
• Samsung Biologics Co., Ltd.
• Scorpius BioManufacturing
• Syngene International Ltd.
• WuXi Biologics

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.